Welcome to our dedicated page for Ginkgo Bioworks Holdings SEC filings (Ticker: DNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ginkgo Bioworks’ synthetic biology foundry files dense reports that mix government biosecurity contracts, milestone-based collaboration revenue, and intricate share-based compensation tables—information that can overwhelm even seasoned analysts. If you have ever searched for “Ginkgo Bioworks insider trading Form 4 transactions” or wondered how to decode a 300-page 10-K, you know the challenge.
Stock Titan solves that problem. Our platform pulls every filing—10-K, 10-Q, 8-K, S-1, DEF 14A and more—directly from EDGAR, then applies AI-powered summaries that turn jargon into plain English. Need the Ginkgo Bioworks quarterly earnings report 10-Q filing? We highlight Foundry capacity metrics and Cell Engineering backlog in seconds. Tracking management moves? Receive Ginkgo Bioworks Form 4 insider transactions real-time, complete with context so you can spot trends before they hit the headlines.
Use cases investors rely on daily:
- Compare Biosecurity and Cell Engineering revenue in the latest Ginkgo Bioworks annual report 10-K simplified.
- Monitor Ginkgo Bioworks executive stock transactions Form 4 alongside option grant details in the proxy statement executive compensation.
- See contract awards and lab expansions inside Ginkgo Bioworks 8-K material events explained.
- Dive deeper with Ginkgo Bioworks earnings report filing analysis generated by our AI.
Whether you’re understanding Ginkgo Bioworks SEC documents with AI for the first time or refining a valuation model, Stock Titan’s real-time updates and expert commentary keep you ahead without wading through technical appendices.
Ginkgo Bioworks (DNA) filed a Form 4 for its CFO showing routine equity activity tied to RSU vesting. On 10/16/2025, restricted stock units were converted to Class A shares via code M in three tranches: 1,174 shares, 312 shares, and 1,061 shares.
On 10/17/2025, the CFO sold 1,312 shares at $13.649 per share under code S to cover tax withholding related to these vestings, as permitted by the company’s equity plans. Following the transactions, the CFO directly beneficially owned 6,738 Class A shares.
DNA filed a Form 144 notice for a proposed sale of 5,609 Class A shares through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of 84,135. The approximate sale date listed is 10/21/2025.
The shares were acquired via restricted stock vesting as compensation on multiple dates in 2024, including 4,062 shares on 05/01/2024 and smaller vestings thereafter, totaling the amount to be sold. The filing lists 47,089,598 shares outstanding for the class. The section on recent activity shows a prior sale of 310 shares on 08/22/2025 for gross proceeds of 3,842.79.
DNA filed a Form 144 notice for a proposed sale of 1,312 shares of Class A common stock with an aggregate market value of $17,907.89, with an approximate sale date of 10/21/2025 on the NYSE through Fidelity Brokerage Services LLC.
The shares were acquired on 10/16/2025 via restricted stock vesting as compensation. In the past three months, Steve Coen sold 310 shares for gross proceeds of $3,842.79. Shares outstanding were 47,089,598; this is a baseline figure, not the amount being offered.
Ginkgo Bioworks Holdings, Inc. (DNA) filing a Form 144 notifies a proposed sale of 2,200 Class A shares held by the reporting person through Fidelity Brokerage Services. The shares were acquired on
Ginkgo Bioworks Holdings, Inc. (DNA) reporting person Coen Steven P., identified as an officer (Chief Financial Officer), sold 5,609 shares of Class A common stock on 10/01/2025 at a reported price of $15 per share under a sales plan intended to comply with Rule 10b5-1. Following the reported disposition, the filing shows the reporting person beneficially owns 5,503 shares, held directly. The Form 4 was signed by an attorney-in-fact, Karen Tepichin, on 10/03/2025. The filing includes an explicit remark that the sale was made pursuant to a Rule 10b5-1 plan and identifies the reporting person as the company’s Chief Financial Officer.
Ginkgo Bioworks director Henry Christian O reported two open-market sales totaling 20,000 shares of Class A common stock. The Form 4 shows a sale of 10,000 shares on 09/08/2025 at a weighted-average price of $10.92 and a sale of 10,000 shares on 09/09/2025 at a weighted-average price of $11.06. After the first sale the filing lists 34,310 shares beneficially owned and after the second sale 24,310 shares beneficially owned, both held directly. The filing includes explanations that the reported prices are weighted averages of multiple transactions within the stated price ranges.
Ginkgo Bioworks (DNA) filed a Form 144 reporting proposed and recent insider sales of Class A common stock. The filer plans to sell 2,200 shares on or about 09/10/2025 through Fidelity Brokerage Services on the NYSE, with an aggregate market value listed as $23,716.00 and total outstanding Class A shares shown as 47,089,598. The filing discloses prior acquisitions by restricted stock vesting on 10/17/2022 (1,866 shares) and 10/18/2022 (334 shares) paid as compensation, and multiple recent sales during June–August 2025 totaling 4,995 shares with gross proceeds reported on individual dates. The filer certifies no undisclosed material adverse information.
Ginkgo Bioworks Holdings, Inc. (DNA) Form 144 notifies the proposed sale of 10,000 Class A shares through Fidelity Brokerage Services with an aggregate market value of $110,599.54. The filing reports the shares were acquired on 03/11/2022 via restricted stock vesting as compensation. The approximate sale date is listed as 09/09/2025 on the NYSE, and the issuer has 47,089,598 shares outstanding. The filer disclosed a prior sale of 10,000 shares on 09/08/2025 that generated gross proceeds of $109,209.34. The notice includes the standard attestation that no undisclosed material adverse information is known.
Ginkgo Bioworks (DNA) Form 144 notice: An insider notified the sale of 10,000 Class A shares through Fidelity Brokerage Services (900 Salem St, Smithfield RI) with an approximate aggregate market value of $109,209.3447,089,598 and an approximate sale date of 09/08/2025. All 10,000 shares were acquired from the issuer as restricted stock vesting on dates between 11/19/2021 and 03/11/2022 and were paid as compensation. The filer reports no securities sold in the past three months.
FAQ
What is the current stock price of Ginkgo Bioworks Holdings (DNA)?
What is the market cap of Ginkgo Bioworks Holdings (DNA)?
